Get the Stockscreener App
3.12
0.34%
-0.0107
After Hours:
3.12
Eupraxia Pharmaceuticals Inc stock is traded at $3.12, with a volume of 6,492.
It is down -0.34% in the last 24 hours and up +24.30% over the past month.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.
See More
Previous Close:
$3.1307
Open:
$3.12
24h Volume:
6,492
Relative Volume:
0.66
Market Cap:
$110.43M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+3.65%
1M Performance:
+24.30%
6M Performance:
+6.12%
1Y Performance:
+0.00%
1-Day Range:
$3.0969
$3.14
1-Week Range:
$2.78
$3.14
52-Week Range:
$2.20
$3.79
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Name
Eupraxia Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare EPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| EPRX | 3.12 | 110.43M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Latest News
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Coverage Initiated at Rodman & Renshaw - Defense World
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Eupraxia Pharmaceuticals files report with SEC - Investing.com
RODMAN&RENSHAW Upgrades Eupraxia Pharmaceuticals (NASDAQ:EPRX) to "Strong-Buy" - MarketBeat
Rodman & Renshaw rates Eupraxia stock Buy on 'groundbreaking delivery tech' - Investing.com Canada
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting - BioSpace
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Now Covered by Rodman & Renshaw - MarketBeat
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024 - PR Newswire
Eupraxia Pharmaceuticals reports regulatory update - Investing.com
Newswire - KelownaNow
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis - Quantisnow
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results - Quantisnow
Finansavisen - Finansavisen
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Down 5.4%What's Next? - MarketBeat
Troutman Pepper Advises Eupraxia Pharmaceuticals in Closing of a Non-Brokered Private Placement - Troutman Pepper
Eupraxia Pharmaceuticals Shares Rise After Completing Private Placement - MarketWatch
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million - Quantisnow
Microstrategy Cl A (MSTR-Q) QuotePress Release - The Globe and Mail
Eupraxia Pharmaceuticals Inc. - Baystreet.ca
Eupraxia Pharmaceuticals Inc (EPRX-T) QuotePress Release - The Globe and Mail
Fennec Pharmaceuticals Inc. - Baystreet.ca
Stocks in play: Eupraxia Pharmaceuticals Inc. - Barchart
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024 - Quantisnow
Eupraxia reports Phase 2b trial success for osteoarthritis treatment - Investing.com India
Eupraxia reports Phase 2b trial success for osteoarthritis treatment By Investing.com - Investing.com Canada
Health Rounds: Steroid injection relieves knee arthritis pain for months - Reuters
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis - StockTitan
Stocks In Play: Eupraxia Pharmaceuticals Inc. - Barchart
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Up 3.4%What's Next? - MarketBeat
Eupraxia Pharmaceuticals reports to SEC on latest developments - Investing.com India
Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results - Barchart
Eupraxia Pharmaceuticals reports to SEC on latest developments By Investing.com - Investing.com South Africa
Eupraxia Pharmaceuticals Highlights Innovation at UEG Week 2024 - TipRanks
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024 - PR Newswire
EPRX stock touches 52-week low at $2.34 amid market challenges - Investing.com Australia
EPRX stock touches 52-week low at $2.34 amid market challenges By Investing.com - Investing.com South Africa
eupraxia pharmaceuticals inc. Earnings dates - RTTNews
Eupraxia Pharmaceuticals expands leadership team - Investing.com India
Eupraxia Pharmaceuticals files report with SEC By Investing.com - Investing.com Canada
Eupraxia Pharmaceuticals expands leadership team By Investing.com - Investing.com South Africa
Eupraxia Pharmaceuticals Enhances Leadership Team - TipRanks
Eupraxia Pharmaceuticals Strengthens Senior Management Team – Company Announcement - Financial Times
Mutual of America Capital Management LLC Sells 1,218 Shares of Euronet Worldwide, Inc. (NASDAQ:EEFT) - Defense World
Itau Unibanco Holding S.A. Buys New Position in Edwards Lifesciences Co. (NYSE:EW) - Defense World
Amalgamated Bank Grows Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Defense World
Eupraxia Pharmaceuticals Showcases Innovative Therapy at ISDE Congress - TipRanks
Eupraxia Pharmaceuticals to present at ISDE Congress for Esophageal Diseases - TipRanks
Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases - Kilgore News Herald
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Up 4.8% - MarketBeat
Eupraxia Pharmaceuticals Inc Stock (EPRX) Financials Data
There is no financial data for Eupraxia Pharmaceuticals Inc (EPRX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.66%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):